The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Opportunistic pulmonary/systemic infections
Publications
Digging into the Histology.
The New England journal of medicine 2023 Oct 05;389;1321-1326 — 2023 Oct 05 — 1321-1326
Sandborn WJ, D'Haens GR, Sands BE, Panaccione R, Ng SC, Lawendy N, Kulisek N, Modesto I, Guo X, Mundayat R, Su C, Vranic I, Panés J
Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme.
Journal of Crohn's & colitis 2023 Apr 03;17 — 2023 Apr 03 — 338-351
Atypical presentation of pneumonia in a patient with rheumatoid arthritis treated with tofacitinib: a case presentation.
BMC rheumatology 2018;2;34 — 2018 — 34
Sandborn WJ, Su C, Sands BE, D'Haens GR, Vermeire S, Schreiber S, Danese S, Feagan BG, Reinisch W, Niezychowski W, Friedman G, Lawendy N, Yu D, Woodworth D, Mukherjee A, Zhang H, Healey P, Panés J,
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.
The New England journal of medicine 2017 May 04;376;1723-1736 — 2017 May 04 — 1723-1736
Pulmonary Cryptococcosis in the Setting of Tofacitinib Therapy for Psoriasis.
Journal of drugs in dermatology : JDD 2015 Aug;14;901-2 — 2015 Aug — 901-2
van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, García Meijide JA, Wagner S, Forejtova S, Zwillich SH, Gruben D, Koncz T, Wallenstein GV, Krishnaswami S, Bradley JD, Wilkinson B,
Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.
The New England journal of medicine 2012 Aug 09;367;508-19 — 2012 Aug 09 — 508-19
Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, Gruben D, Wallenstein GV, Zwillich SH, Kanik KS,
Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis.
The New England journal of medicine 2012 Aug 09;367;495-507 — 2012 Aug 09 — 495-507
Vincenti F, Tedesco Silva H, Busque S, O'Connell P, Friedewald J, Cibrik D, Budde K, Yoshida A, Cohney S, Weimar W, Kim YS, Lawendy N, Lan SP, Kudlacz E, Krishnaswami S, Chan G
Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2012 Sep;12;2446-56 — 2012 Sep — 2446-56